Policy

Why Most Favored Nation pricing is becoming a political imperative

Explore how Most Favored Nation (MFN) pricing could impact pharmaceutical pricing, reimbursement, market access, and evidence strategies for life sciences organizations.

First Joint Clinical Assessment (JCA) Report Published: Implications for Evidence Strategy in Europe

Explore the key findings from the first Joint Clinical Assessment (JCA) report and what they mean for comparator selection, evidence generation, and submission strategy across Europe.

Spain has just redrawn the rules of health technology assessment

Explore how Spain’s new health technology assessment framework is reshaping market access, evidence strategy, pricing decisions and lifecycle planning.

How most favored nation policy is reshaping pharmaceutical pricing and market access

Discover how Most Favored Nation (MFN) policy impacts U.S. drug pricing and market access, from CMS enforcement to launch planning. Get the whitepaper now.

Most favored nation (MFN) exposure assessment

Implementation of a Most Favored Nation policy creates a great deal of uncertainty. We built this tool to help understand the impact for your business.

Calculate your impact now